

1. **Fenyő EM**, Klein E, Klein G, and Swiech K. Selection of an immunoresistant Moloney lymphoma subline with decreased concentration of tumor-specific surface antigens. *J Natl Cancer Inst*, **40**:69-89, 1968.
2. **Fenyő EM**, Biberfeld P and Klein E. Studies on the relation between virus release and cellular immunosensitivity in Moloney lymphomas. *J Natl Cancer Inst*, **42**:837-855, 1969.
3. Klein E and **Fenyő EM**. Immunoresistance associated with decrease of surface antigen expression and virus maturation in Moloney virus induced lymphoma cells. *In: Defectiveness of oncogenic viruses, Eds Boiron and Chuat, Royamaunt, pp. 269-272, 1969.*
4. Nadkarni J S, Nadkarni J J, Clifford P, Manolov G, **Fenyő EM** and Klein E. Characteristics of new cell lines derived from Burkitt lymphomas. *Cancer* **23**: 64-79, 1969.
5. Clifford P, Gripenberg U, Klein E, **Fenyő EM** and Manolov G. Treatment of Burkitt's lymphoma. *The Lancet*, August 31, pp 517-518, 1968.
6. Nordenskjöld B, Klein E, Tachibana T and **Fenyő EM**. Tissue culture assay for Moloney leukemia virus. *J Natl Cancer Inst* **44**:403-412, 1970.
7. Gergely L, Cikes M, Klein E, **Fenyő EM** and Friberg S. The sensitivity of JLS-V9 cells to Moloney leukemia virus in relation to cell cycle. *Exp Cell Res* **64** 230-232, 1970.
8. **Fenyő EM**, Nordenskjöld B, and Klein E. Membrane immunofluorescence on cultured indicator cells as a measure of virus production by mouse L cells and by two Moloney lymphoma sublines differing in immunosensitivity. *Ann NY Acad Sci* **177**: 121-129, 1971.
9. **Fenyő EM**, Grundner G, Klein G, Klein E and Harris H. Surface antigens and release of virus in hybrid cells produced by the fusion of A9 fibroblasts with Moloney lymphoma cells. *Exp Cell Res* **68**:323-331, 1971.
10. Grundner G, **Fenyő EM**, Klein G, Klein E, Bregula U and Harris H. Surface antigen expression in malignant sublines derived from hybrid cells of low malignancy. *Exp Cell Res* **68**:315-322, 1971.
11. **Fenyő EM**, Grundner G and Klein E. Studies on the expression of leukemia virus-controlled cell surface antigen and infectious virus release. *Vth International Symp on Comp Leuk Res, Padova, Bibl Haematol* **39**:712-719, 1971.
12. **Fenyő EM**. Expression of Moloney leukemia virus-controlled cell surface antigen in relation to virus release. *Transplantation Proc Vol III, No 3*, pp 1185-1188, 1971.

13. Grundner G, **Fenyö EM**, Strouk V and Klein E. Murine leukemia virus assay techniques: A comparative study, Proc Soc Exp Biol Med **140**:378-382, 1972.
14. Strouk V, Grundner G, **Fenyö E M**, Lamon E, Skurzak, H and Klein G. Lack of distinctive surface antigen on cells transformed by murine sarcoma viurs. J Exp Med **136**: 344-352, 1972.
15. Wiener F, **Fenyö EM**, Klein G and Harris H. Fusion of tumor cells with host cells. Nature New Biol **238**: 155-159, 1972.
16. **Fenyö EM**, Grundner G. Characteristics of murine C-type viruses. I. Independent assortment of infectivity in one *in vivo* and four *in vitro* assays. Int J Cancer **12**:452-462, 1973.
17. **Fenyö EM**, Grundner G, Wiener F, Klein E, Klein G and Harris H. The influence of the partner cell on the production of L virus and the expression of viral surface antigen in hybrid cells. J Exp Med **137**:1240-1255, 1973.
18. **Fenyö EM**, Peebles P T, Wahlström, A, Klein E and Cochran A J. Changes in cell surface properties during the *in vivo* growth of Moloney lymphoma. Isr J Med Sci **9**:239-250, 1973.
19. **Fenyö EM**, Wiener F, Klein G and Harris H. Selection of tumor-host cell hybrids from polyoma virus- and methyl-cholanthrene-induced ascites sarcomas. J Natl Cancer Inst **51**:1865-1875, 1973.
20. Lamon E W, Klein E Andersson, B, **Fenyö EM** and Skurzak H M. The humoral antibody response to a primary viral nneoplasm (MSV) through its entire course in BALB/c mice. Int J Cancer **12**:637-645, 1973.
21. Lamon E W, Andersson, B, Wigzell H, **Fenyö EM** and Klein E. The immune response to primary Moloney sarcoma virus turmors in BALB/c mice: Cellular and humoral activity of long-term regressors. Int J Cancer **13**: 91-104, 1974.
22. **Fenyö EM**, Grundner G and Klein E. Virus associated surface antigens on L cells and Moloney lymphoma cells. J Natl Cancer Inst **52**:743-751, 1974.
23. **Fenyö EM**, Grundner G and Klein E. Changes in the properties of the resident L virus in somatic cell hybrid lines. Exp Cell Res **87**: 326-332, 1974.
24. Grundner G, **Fenyö EM** and Klein E. Characteristics of murine C-type viruses. III. Antigenic conversion and focus induction. Int J Cancer **13**:412-419, 1974.
25. Grundner G, **Fenyö EM** and Klein E. Characteristics of murine C-type viruses. IV. The virus produced by Ehrlich tumor cells and its hybrids with mouse L cells. Int J Cancer **13**: 420-427, 1974.
26. Wiener F, **Fenyö EM** and Klein G. Tumor-host cell hybrids in radiochimeras. Proc Natl Acad Sci **71**: 148-152, 1974.

27. **Fenyö EM**, Nazerian K and Klein E. Characteristics of murine C-type viruses. II. The behaviour of viruses resident in various cell lines and their hybrids on BALB/3T3 and mouse embryo fibroblast cultures. *Virology* **59**:574-579, 1974.
28. **Fenyö EM**, Grundner G, Nazerian K and Clements G. Reassortment of mouse C-type virus markers in somatic cell hybrids. *Akademisk avhandling, Stockholm* 1974.
29. Lamon E W, Gatti, R A, Kiessling R and **Fenyö EM**. Comparison of the allospecific and viral-specific immune responses to irradiated versus formaldehyde-fixed allogeneic Moloney lymphoma cells in CBA mice. *Cancer Res.* **35**:962-969, 1975.
30. Wiener F, **Fenyö EM**, Klein G and Harris H. Fusion of tumor cells with host cells. *In: Somatic Cell Hybridization. Eds R L Davidson and F de la Cruz, pp 105-118, Raven Press, New York, 1974.*
31. Wiener F, **Fenyö EM**, Klein G and Davies AJS. Tumor-host cell hybrids in radiochimeras reconstituted with bone marrow and thymus grafts. *Somatic Cell Genetics* **2**: 81-92, 1976.
32. **Fenyö EM** and Klein G. Independence of Moloney virus-induced cell-surface antigen and membrane-associated virion antigens in immuno-selected lymphoma sublines. *Nature* **260**:355-357, 1976.
33. Clements GB, **Fenyö EM** and Klein G. *In vitro* derived mouse A9 cell clones differing in malignancy: Analysis by somatic cell hybridization with YACIR lymphoma cell clones. *Proc Natl Acad Sci* **73**:2004-2007, 1976.
34. Becker S, **Fenyö EM**, and Klein E: The "natural killer" cell in the mouse does not require H-2 homology and is not directed against type or group-specific antigens of murine C-viral proteins. *Europ J Immunol* **6**:882-885, 1976.
35. Siegert W, **Fenyö EM** and Klein G: Separation of the Moloney virus-induced cell surface antigen from known membrane-associated virion proteins. *Int J Cancer* **20**:75-82, 1977.
36. **Fenyö EM**, Yefenof E, Klein E and Klein G: Immunization of mice with syngeneic Moloney lymphoma cells induces separate antibodies against virion envelope glycoprotein and virus-induced cell surface antigens. *J Exp Med* **146**:1521-1533, 1977.
37. Troy FA, **Fenyö EM**, and Klein G: Moloney leukemia virus-induced cell surface antigen: Detection and characterization in NaDodSO₄ gels. *Proc Natl Acad Sci* **74**:5270-5274, 1977.
38. Kuzumaki N, **Fenyö EM** and Klein G: Augmented immunogenicity of low antigenic rat tumors after superinfection with endogenous murine C-type virus in nude mice. *Int J Cancer* **21**:62-66, 1978.

39. **Fenyö EM**, Troy FA, Siegert W, and Klein E: Moloney leukemia virus-determined cell membrane antigens. VIIIth Internatl Symp Comp Res Leuk, Amsterdam, pp 331-336, 1977
40. Ber R, **Fenyö EM**, and Klein G: Cell surface antigen expression in cytoplasts and karyoplasts of mouse L cells. *Cancer Letters* **5**:69-73, 1978.
41. Ber R, Wiener F, and **Fenyö EM**: Proof of in vivo fusion of murine tumor cells with host cells by universal fusers. *J Natl Cancer Inst* **60**:931-933, 1978.
42. Kiessling R, Haller O, **Fenyö EM**, Steinitz M and Klein G: Mouse natural killer (NK) cell activity against human cell lines is not influenced by superinfection of the target cell with xenotropic murine C-type virus. *Int J Cancer* **21**:460-465, 1978.
43. **Fenyö EM**: The Moloney leukemia virus-determined cell surface antigen: Separation from cell membrane-associated virion proteins. Proc of the Conf on Biological Markers of Neoplasia: Basic and Applied Aspects. May 22-26, 1978.
44. **Fenyö EM**, and Troy FA: Altered Moloney leukemia virus-determined cell surface antigens in lymphoma sublines selected for immunoresistance. In: *"Current Trends in Tumor Immunology"*, Garland Publishing, Inc, New York, 1978.
45. Roder JC, Rosen A, **Fenyö EM**, and Troy FA: Target-effector interaction in the natural killer cell system: Isolation of the target structures. *Proc Natl Acad Sci* **76**:1405-1409, 1979.
46. Karande A, Yefenof E, **Fenyö EM** and Klein G: Moloney lymphoma cells express a polyprotein containing the *gag* gene-coded p15 and the Moloney leukemia virus-induced cell surface antigen (MCSA). *Int J Cancer* **23**:508-513, 1979.
47. Bubenik J, Perlmann P, **Fenyö EM**, Jandlova T, Suhajova E, and Malkovsky M: Inverse correlation between cell-surface adhesiveness and malignancy in mouse fibro-blastoid cell lines. *Int J Cancer* **23**:392-396, 1979.
48. Kuzumak N, **Fenyö EM**, Klein E, and Klein G: Protective effect of murine sarcoma virus-superinfected mouse tumor cells against outgrowth of corresponding non-infected tumor. *Transplantation* **26**:304-307, 1978.
49. Kurth R, **Fenyö EM**, Klein E and Essex M: Cell surface antigens induced by RNA tumor viruses. *Nature* **279**:197-201, 1979.
- 49a. Kuzumaki N, **Fenyö EM**, Giovanella BC and Klein G: Increased immunogenicity of low-antigenic rat tumors after superinfection with endogenous murine C-type virus in nude mice. *Int J Cancer* **21**:62-66, 1978.
50. **Fenyö EM**, Klein G, Povey S, Spira J, Wiener F, and Harris H: Suppression and reappearance of N-tropic L virus production in somatic cell hybrids after introduction and loss of chromosomes carrying Fv-1^b. *Europ J Cancer* **16**:357-368, 1980.

51. Åsjö B, **Fenyö EM**, Spira J, and Klein G: Appearance and distribution of virally determined antigens in lymphoid tissues of mice during leukemogenesis by Moloney leukemia virus. *Leukemia Research* **4**:89-103, 1980.
52. Troy FA and **Fenyö EM**: Structural differentiation between the Moloney leukemia virus-determined cell membrane antigen and virion structural proteins. *Proc of the Fourth Internatl Symp on Glycoconjugates*, Academic Press Inc, pp 1085-90, 1979.
53. **Fenyö EM**, Åsjö B and Spira J: Moloney murine leukemia virus leukemogenesis: Antigenic and karyological changes in lymphoid organs of mice. *In: Advances in Comparative Leukemia Research 157-159*. Eds Yohn, Lapin, Blakelee. 1979
54. Panet A, Falk H, **Fenyö EM** and Klein G: Restriction of murine leukemia proviral gene expression in somatic mouse cell hybrids. *Virology* **106**:197-206, 1980.
55. Åsjö B, Buetti E, **Fenyö EM**, Diggelman H and Klein G: Moloney murine leukemia virus variants with distinct p30 peptide maps are associated with different clinical types of leukemia. *Europ J Cancer* **17**:187-192, 1981.
56. Bubenik J, Perlmann P, Biberfeld P, **Fenyö EM**, Malkovsky M and Suhajova E: Cell surface adhesiveness of Moloney lymphoma sublines. *Microbiologica* **3**:167-176, 1980.
57. Klein E, **Fenyö EM** and Åsjö B: Immune response against Moloney virus induced leukemia cells in mice. *Proc of the Internatl Symp on "Leukemia, Lymphomas and Papillomas: Comparative Aspects"*, München, 1980.
58. Åsjö B, **Fenyö EM** and Klein G: Moloney virus (M-MuLV) leukemogenesis: Virus spread, antibody production and antigenic expression in neonatally virus-inoculated young mice. *Int J Cancer* **28**:65-70, 1981.
59. **Fenyö EM**, Åsjö B and Spira J: Surface antigens on Moloney leukemia cells: Lack of correlation with clinical form and karyotype. *Advances in Comparative Leukemia Research*, 1981.
60. Ber R, **Fenyö EM**, Andersen-Nexo and Skoog L: Decay of Moloney leukemia virus production after enucleation of chronically infected mouse cells. *Isr J Med Sci* **17**:690-696, 1981.
61. Åsjö B, Skoog L, **Fenyö EM** and Klein G: Different T cell subtypes are associated with pathologically distinct forms of Moloney leukemia virus (M-MuLV)-induced lymphoma. *Int J Cancer* **29**:163-167.
62. Åsjö B, **Fenyö EM** and Spira J: Antigenic and chromosomal changes in thymus and spleen of BALM/Mo mice during leukemogenesis. *Leukemia Res* **6**:413-419, 1982.
63. Åsjö B, Klein E, **Fenyö EM** and Klein G: The role of humoral immunity and the contribution of the F₁ anti-parenteral effect in the rejection of a Moloney leukemia virus-induced lymphoma graft. *Cancer Immunology and Immunotherapy* **15**:92-95, 1983.
64. **Fenyö EM**, Wiener F, Rafnar B and Åsjö B: Tumors arising from Abelson leukemia virus-infected spleen cells in pristaneprimed BALB/c mice produce antibodies to preselected antigens. *Advances in Comparative Leukemia Research*, 1983.

65. **Fenyö EM** and Wahren B: Viruses and tumors. *In: Textbook of Medical Virology (Eds Lycke E and Norrby E)*. 1983.
66. Åsjö B, Skoog L, Palminger I, Wiener F, Isaak D, Cerny J and **Fenyö EM**. Influence of genotype and the organ of origin on the subtype of T-cell in Moloney lymphomas induced by transfer of preleukemic cells from athymic and thymus-bearing mice. *Cancer Research* **45**:1040-1045, 1985.
67. Åsjö B and **Fenyö EM**: BALB/c and CBA mice differ in the subtype of T cell involved in Moloney murine leukemia virus induced lymphomas. *Leukemia Research* **10**:339-344, 1986.
68. Åsjö B, Morfeldt-Månson L, Albert J, Biberfeld G, Karlsson A, Lidman K and **Fenyö EM**: Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. *Lancet* ii, 660-662, 1986.
- 68a. Åsjö B, Morfeldt-Månson L, **Fenyö EM**, Böttiger B, Biberfeld G and Espmark Å: LAV/HTLV-III - nya rön om egenskaper, isolering, vaccination och terapi. *Läkartidningen* **82**:1870-1875, 1985.
69. Chiodi F, Åsjö B, **Fenyö EM**, Norkrans G, Hagberg L and Albert J: Isolation of human immunodeficiency virus from cerebrospinal fluid of antibody-positive virus carrier without neurological symptoms. *Letter Lancet* ii, 1276-1277, 1986.
70. Åsjö B, Ivhed I, Gidlund M, Fuerstenberg S, **Fenyö EM**, Nilsson K and Wigzell H: Susceptibility to infection by the human immunodeficiency virus (HIV) correlate with T4 expression in a parental monocytoid cell line and its subclones. *Virology* **157**:359-365, 1987.
71. Chiodi F, Fuerstenberg S, Gidlund M, Åsjö B, and **Fenyö EM**: Infection of brain-derived cells with the human immunodeficiency virus. *J Virology* **61**:1244-1247, 1987.
72. Åsjö B, Morfeldt-Månson L, **Fenyö EM** and Biberfeld G: *In vitro* properties of AIDS virus isolated from infected individuals; possible clinical correlation. *In: AIDS: Diagnosi, Prevenzione, Terapia. Soleil Libreria Ed Int, p:53-61*. 1988
73. **Fenyö EM** and Åsjö B: Growth of the HTLV-IIIB strain of human immunodeficiency virus in different cell types. *In: Modern Trends in Human Leukemia VII. Eds Neth, Gallo, Greaves, Kabisch. Springer Verlag, Berlin, Heidelberg, pp 436-439*, 1987
74. Albert J, Bredberg U, Chiodi F, Böttiger B, **Fenyö EM**, Norrby E and Biberfeld G: A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II and HTLV-IIIB. *AIDS Res Hum Retroviruses* **3**:3-10, 1987.
75. **Fenyö EM**: Distinct *in vitro* replication patterns of human immunodeficiency virus isolates. *In: Molecular Biology and Differentiation of Cancer Cells. Lapis/Eckhardt (eds) Karger, Basel/Akadémiai Kiado, Budapest, vol 2 pp 305-310*, 1987.
76. Albert J, Gaines H, Sönnnerborg A, Nyström G, Pehrson PO, Chiodi F, von Sydow M, Moberg L, Lidman K, Christensson B, Åsjö B, and **Fenyö EM**: Isolation of human immunodeficiency virus (HIV) from plasma during primary HIV infection. *J Med Virol* **23**:67-73, 1987.
77. Chiodi F, Bredberg U, Biberfeld G, Böttiger B, Albert J, Åsjö B, **Fenyö EM**, and Norrby E: Radioimmunoprecipitation and Western blotting with sera of human immunodeficiency virus infected patients: A comparative study. *AIDS Res Hum Retroviruses* **3**:165-175, 1987.

- 77a. **Fenyö EM** and Norrby E: Vaccination mot AIDS. *Läkartidningen*, **84**:1133-1140, 1987.
78. Ljunggren K, **Fenyö EM**, Biberfeld G and Jondal M: Detection of antibodies which mediate human immunodeficiency virus-specific cellular cytotoxicity (ADCC) *in vitro*. *J Immunol Methods* **104**:7-14, 1987.
79. Ljunggren K, Böttiger B, Biberfeld G, Karlson A, **Fenyö EM** and Jondal M: Antibody-dependent cellular cytotoxicity (ADCC)-inducing antibodies against human immunodeficiency virus (HIV): Presence at different clinical stages. *J Immunol* **139**:2263-2267, 1987.
80. Gaines H, von Sydow M, Sönnnerborg A, Albert J, Czajkowski J, Pehrsson PO, Chiodi F, Moberg L, **Fenyö EM**, Åsjö B and Forsgren M: Antibody response in primary human immunodeficiency virus infection. *The Lancet* **i**: 1249-1253, 1987.
81. Arya SK, Beaver B, Ensoli B, Kanki PJ, Albert J, **Fenyö EM**, Biberfeld G, Zagury JF, Laure F, Essex M, Norrby E, Wong-Staal F and Gallo RC: Like HTLV-III/LAV, HTLV-IV, LAV-2, SBL-6669 and STLV-III possess transactivating capacity. *Letter to Nature* **328**:548-550, 1987.
82. Franchini G, Collalti E, Arya SK, **Fenyö EM**, Biberfeld G, Zagury JF, Kanki PJ, Wong-Staal F, and Gallo RC: Genetic analysis of a new subgroup of human and simian T-lymphotropic retroviruses: HTLV-IV, LAV-2, SBL-6669 and STLV-III. *AIDS Res and Hum Retroviruses* **3**:11-18, 1987.
83. Chiodi F, von Gegerfelt A, Albert J, **Fenyö EM** Gaines H, von Sydow M, Biberfeld G, Parks E and Norrby E: Site-directed ELISA with synthetic peptides representing the HIV transmembrane glycoprotein. *J Med Virol* **23**:1-9, 1987.
84. Åsjö B, Albert J, Chiodi F and **Fenyö EM**: Improved tissue culture technique for production of poorly replicating human immunodeficiency virus isolates. *J Virol Methods* **19**:191-196, 1988.
85. Ljunggren K, Chiodi F, Biberfeld G, Norrby E, Jondal M and **Fenyö EM**: Lack of cross-reaction in antibody-dependent cellular cytotoxicity between HIV and HIV-related West African strains. *J Immunol* **140**:602-605, 1988.
86. Albert J, Pehrson PO, Schulman S, Håkansson C, Lövhagen GH, Berglund O, Beckman S, and **Fenyö EM**: HIV isolation and antigen detection in infected individuals and their seronegative sexual partners. *AIDS* **2**:107-111, 1988.
87. Wahren B, Chiodi F, Ljunggren K, Putney S, Bolognesi D, Kurth R, Gallo R and **Fenyö EM**: B and T cell reactivities after immunization of macaques with HIV subcomponents. *AIDS Res Hum Retroviruses* **4**:199-210, 1988.
88. Koga Y, Lindström E, **Fenyö EM**, Wigzell H and Mak TW: High levels of heterodisperse RNAs accumulate in T cells infected with human immunodeficiency virus and in normal thymocytes. *Proc Natl Acad Sci USA* **85**:4521-4525, 1988.
89. Chiodi F, Sönnnerborg A, Albert J, Gaines H, Norkrans G, Hagberg L, Åsjö B, Strannegård Ö and **Fenyö EM**: Human immunodeficiency virus infection of the brain. I. Virus isolation and detection of HIV specific antibodies in the cerebrospinal fluid of patients with varying clinical conditions. *J Neurol Sci* **85**:245-257, 1988.
90. **Fenyö EM**, Morfeldt-Månson L, Chiodi F, Lind B, von Gegerfelt A, Albert J, Olausson E and Åsjö B: Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. *J Virol* **62**:4414-4419, 1988.

91. Goudsmit J, Ljunggren K, Smit L, Jondal M and **Fenyö EM**: Biological significance of the antibody response to HIV antigens expressed on the cell surface. *Arch Virol* **103**:189-206, 1988.
92. **Fenyö EM** and Wahren B: Virus som orsak till tumörer. *In: Medicinsk Virologi, Eds E Lycke and E Norrby, Almqvist and Wiksell, pp184-198.* 1987
93. **Fenyö EM** and Åsjö B: Retrovirus. *In: Medicinsk Virologi, Eds E Lycke and E Norrby, Almqvist and Wiksell, pp 297-304.* 1987
94. Chiodi F, Norkrans G, Hagberg L, Sönnernborg A, Gaines H, Froland S, **Fenyö EM**, Norrby E and Vandvik B: Human immunodeficiency virus-infection of the brain. II. Detection of intrathecally synthesized antibodies by enzyme-linked immunosorbent assay and imprint immunofixation. *J Neurol Sci* **87**:37-48, 1988.
95. Wigzell H, Åsjö B, **Fenyö EM**, Lundin K, Matsuda S, Nilsson K, Ramstedt U and Gidlund M: Monocytes and HIV infection. *In: Immunobiology and Pathogenesis of Persistent Virus Infection, Ed C Lopez, pp 223-233.* 1988
96. **Fenyö EM**, Åsjö B, Norrby E and Albert J: Humant immunbristvirus - kunskaps-explosion inom virologin. *Läkartidningen* **85**:420-424, 1988.
97. Chiodi F, Albert J, Olausson E, Norkrans G, Hagberg L, Sönnernborg A, Åsjö B and **Fenyö EM**: Isolation frequency of human immunodeficiency virus from cerebrospinal fluid and blood of patients with varying severity of HIV infection. *AIDS Res and Hum Retroviruses* **4**:351-358, 1988.
98. Böttiger B, Ljunggren K, Karlsson A, Krohn K, **Fenyö EM**, Jondal M, and Biberfeld G: Neutralizing antibodies in relation to antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus type 1. *Clin Exp Immunol* **73**:339-342, 1988.
99. Kövamees J, Sheshberadaran H, Chiodi F, Schwartz S, Örvell C, **Fenyö EM** and Norrby E. Accentuated antibody response to paramyxoviruses in individuals infected with human immunodeficiency virus (HIV). *J Med Virol* **26**:41,48, 1988.
100. Ernberg I, Biberfeld P, **Fenyö EM**, Lycke E, Pettersson U and Weiland O: Cancer hos människa orsakad av virus - en epidemiologisk översikt. *Läkartidningen* **85**:2746-2753, 1988.
101. Ljunggren K, Karlsson A, **Fenyö EM** and Jondal M. Natural and antibody-dependent cytotoxicity in different clinical stages of human immunodeficiency virus type 1 infection. *Clin Exp Immunol* **75**:184-18, 1989.
102. Matsuda S, Gidlund M, Chiodi F, Cafaro A, Nygren A, Morein B, Nilsson K, **Fenyö EM** and Wigzell H. Enhancement of human immunodeficiency virus (HIV) replication in human monocytes by low titres of anti-HIV antibodies *in vitro*. *Scand J Immunol* **30**:425-434, 1989.
103. Ljunggren K, Biberfeld G, Jondal M and **Fenyö EM**. Antibody-dependent cellular cytotoxicity detects group and strain specific antigens among HIV-1 and HIV-2/SIV_{mac} isolates. *J Virol* **63**:3376-3381, 1989.
104. Ljunggren K, Jondal M, Biberfeld G, **Fenyö EM** and Norrby E. HIV-1 and HIV-2/SIV_{mac} type and strain-specific antibody-dependent cellular cytotoxicity. *In: Vaccines 1989, Cold Spring Harbor, Ed Brown et al, pp 159-161.*
105. Franchini G, Fargnoli KA, Giombini F, Jagodzinski L, de Rossi A, Bosch M, Biberfeld G, **Fenyö EM**, Albert J, Gallo RC and Wong-Staal F. Molecular and

- biological characterization of a replication competent human immunodeficiency type 2 (HIV-2) proviral clone. *Proc Natl Acad Sci USA* **86**:2433-2437, 1989.
106. Ljunggren K, Chiodi F, Broliden P-A, Albert J, Norkrans G, Hagberg L, Jondal M and **Fenyö EM**. HIV type 1-specific antibodies in cerebrospinal fluid mediate cellular cytotoxicity and neutralisation. *AIDS Res Hum Retroviruses* **5**:629-638, 1989.
 107. Sundqvist V-A, Albert J, Ohlsson E, Hinkula J, **Fenyö EM**, and Wahren B. HIV-1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics. *J Med Virol* **29**:170-75, 1989.
 108. Albert J, Böttiger B, Biberfeld G and **Fenyö EM**. Replicative and cytopathic characteristics of HIV-2 and severity of infection. *Lancet* **i**:852-853, 1989.
 109. Chiodi F, Valentin A, Keys B, Schwartz S, Åsjö B, Gartner S, Popovic M, Albert J, Sundqvist V-A and **Fenyö EM**. Biological characterization of paired human immunodeficiency virus typ 1 isolates from blood and cerebrospinal fluid. *Virology* **137**:178-187, 1989.
 110. Schwartz S, Felber BK, **Fenyö EM** and Pavlakis GN. Rapidly and slowly replicating HIV-1 isolates can be distinguished according to target cell tropism in T-cell and monocyte cell lines. *Proc Natl Acad Sci USA* **86**:7200-7203, 1989.
 111. Ljunggren K, Moschese V, Broliden P-A, Giaquinto C, Quinti I, **Fenyö EM**, Wahren B, Rossi P and Jondal M. Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to HIV-1-infected mothers. *J Inf Dis* **161**:198-202, 1990.
 112. Fuchs D, Albert J, Åsjö B, **Fenyö EM**, Reibnegger G, and Wachter H. Association between serum neopterin concentrations and in vitro replicative capacity of HIV-1 isolates. *J Inf Dis* **160**:724-725. 1989.
 113. Åsjö B, Sharma UK, Morfeldt-Månson L, Magnusson A, Barkhem T, Albert J, Olausson E, von Gegerfelt A, Lind B, Biberfeld P and **Fenyö EM**. Naturally occurring HIV-1 isolates with differences in replicative capacity are distinguished by in situ hybridization of infected cells. *AIDS Res and Human Retroviruses* **6**:1177-1182, 1990.
 114. Albert J, Abrahamsson B, Nagy K, Aurelius E, Gaines H, Krook A, Nyström G, and **Fenyö EM**. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. *AIDS* **4**:107-112, 1990.
 115. **Fenyö EM**, Albert J, and Åsjö B. Replicative capacity, cytopathic effect and cell tropism of HIV. *AIDS* **3** (suppl 1):5-12. 1989.
 116. Albert J, Nauclér A, Böttiger B, Broliden P-A, Albino P, Ouattara SA, Björkegren C, Valentin A, Biberfeld G, and **Fenyö EM**. Replicative capacity of HIV-2, like HIV-1, correlates with severity of immunodeficiency. *AIDS* **4**:291-295, 1990.
 117. Valentin A, Albert J, **Fenyö EM**, and Åsjö B. HIV-1 infection of normal human macrophage cultures; implication for silent infection. *Virology* **177**:790-794, 1990.
 118. Schwartz S, Felber BK, Benko DM, **Fenyö EM**, and Pavlakis GN. Cloning and functional analysis of multiply spliced mRNA species of human immunodeficiency virus type-1. *J Virol* **64**:2519-2529, 1990.

119. Schwartz S, Felber BK, **Fenyö EM**, and Pavlakis GN. Env and Vpu proteins of human immunodeficiency virus type-1 are produced from multiple bicistronic mRNAs. *J Virol* **64**:5448-5456, 1990.
120. Albert J, and **Fenyö EM**. Simple, sensitive and specific detection of human immunodeficiency virus type 1 in clinical specimens by polymerase chain reaction with nested primers. *J Clin Microbiol* **28**:1560-1564, 1990.
121. Fredriksson R, Stålhandske P, von Gegerfelt A, Lind B, Åman P, Rassart E, and **Fenyö EM**. Biological characterization of infectious molecular clones derived from a human immunodeficiency virus type-1 isolate with rapid/high replicative capacity. *Virology* **181**:55-61, 1991.
122. **Fenyö EM**, and Norrby E. Biological variation of human immunodeficiency viruses and the evolution of the late pathogenic infection in vivo. *AIDS Res Rev*, Vol. 1 Eds. Koff, Wong-Stahl, Kennedy, pp 149-164, 1991.
123. Böttiger D, Keys B, Putkonen P, Walther L, **Fenyö EM**, Norrby E, Öberg B, and Chiodi F. Isolation and characterization of simian immunodeficiency virus (SIV_{SM}) isolates from blood and brain of experimentally infected macaques. *AIDS* **5**:445-449, 1991.
124. Unge T, Ahola H, Bhikhabhai R, Bäckbro K, Lövgren S, **Fenyö EM**, Honigman A, Panet A, Gronowitz JS, and Strandberg B. Expression, purification and crystallization of the HIV-1 reverse transcriptase (RT). *AIDS Res Hum Retroviruses* **6**:1297-1303, 1990.
125. Wahlberg J, Albert J, Lundeberg J, von Gegerfelt A, Broliden K, Utter G, **Fenyö EM**, and Uhlén M. Analysis of the V3 Loop in neutralization-resistant human immunodeficiency virus type 1 variants by direct solid-phase DNA sequencing. *AIDS Res Hum Retroviruses* **7**, 12:983-990. 1991.
126. Scarlatti G, Lombardi V, Plebani A, Principi N, Chiara V, Ferraris G, Bucceri A, **Fenyö EM**, Wigzell H, Rossi P, and Albert J: Polymerase chain reaction, virus isolation and antigen assay in HIV-1 antibody positive mothers and their children. *AIDS* **5**: 1173-1178. 1991.
127. Broliden P-A, von Gegerfelt A, Clapham P, Rosen J, **Fenyö EM**, Wahren B, and Broliden K. Identification of human neutralizing regions of the human immunodeficiency virus type-1 envelope glycoproteins. *Proc Natl Acad Sci USA* **89**, 461-465, 1992.
128. Chiodi F, and **Fenyö EM**. Neurotropism of Human Immunodeficiency Virus. *Brain Pathol* **1**:185-191. 1991.
129. Albert J, and **Fenyö EM**. Diagnosis of human immunodeficiency virus infection by PCR. In: *Diagnosis of Human Viruses by polymerase chain reaction (PCR). Technology*. Eds Darai, Becker 1992, pp 3-15.
130. von Gegerfelt A, Albert J, Morfeldt-Månson L, Broliden K, and **Fenyö EM**. Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease. *Virology* **185**, 162-168. 1991.
131. Örvell C, Unge T, Bhikhabhai R, Bäckbro K, Rudén U, Strandberg B, Wahren B, and **Fenyö EM**. Immunological characterization of the HIV-1 reverse transcriptase protein by the use of monoclonal antibodies. *J Gen Virol* **72**:1913-1918. 1991.

132. Norrby E, Putkonen P, Albert J, and **Fenyö EM**. Immunodominant antigenic sites in primate immunodeficiency viruses and in vivo protection. *Biotechnol Therapeutics* **2**, 21-29, 1991.
133. Chiodi F, Keys B, Albert J, Hagberg L, Lundeberg J, Uhlén M, **Fenyö EM**, and Norkrans, G. HIV-1 is present in the cerebrospinal fluid of the majority of infected individuals. *J Clin Microbiol* **30**, 1768-1771, 1992.
134. von Gegerfelt A, Chiodi F, Keys B Norkrans G, Hagberg L, **Fenyö EM** and Broliden. Lack of autologous neutralizing antibodies in the cerebrospinal fluid of HIV-1 infected individuals. *AIDS Res and Hum Retroviruses*, **8**:1133-1137. 1992.
135. **Fenyö EM**. Viral pathogenesis and heterogeneity. In: *Frontiers of Infectious Diseases. "Focus on HIV"*. Eds. Levy JA, Neu HC, Weiss R; London. Churchill Livingstone Special Projects, pp 27-43, 1993.
136. Scarlatti, G, Albert, J, Rossi, P, Hodara, V, Biraghi, P, Muggiasca, L, and **Fenyö EM**. Mother-to-child transmission of HIV-1: Correlation with neutralising antibodies against primary isolates. *J Inf Dis*. **168**:207-210, 1993
137. Scarlatti, G, Leitner, T, Halapi, E, Wahlberg, J, Marchisio, P, Clerici-Schoeller M A, Wigzell, H, **Fenyö EM**, Albert; J, Uhlén M and Rossi, P. Comparison of V3 sequences from HIV-1 infected children to the RNA and DNA virus population of their mothers. *Proc Natl Acad Sci, USA* **90**, 1721-1725, 1993.
138. Leitner, T, Halapi, E, Scarlatti, G, Rossi, P, Albert J, **Fenyö EM** and Uhlén, M. Analysis of heterogeneous viral populations by direct DNA sequencing. *Biotechniques*. **15**:120-127, 1993
139. Tan W, Fredriksson R, Björndal Å, Balfe P and **Fenyö EM**. Cotransfection of HIV-1 molecular clones with restricted cell tropism may yield progeny virus with altered phenotype. *AIDS Res Hum Retroviruses* **9**, 321-329, 1993.
140. Fiore JR, Jansson M, Scarlatti G, Angarano G, Lo Caputo S, Buccoliero G, Rossi P, **Fenyö EM**, and Pastore G. Correlation between seroreactivity to HIV-1 V3 loop peptides and male-to-female heterosexual transmission. *AIDS* **7**, 29-31, 1993.
141. Björling E, Scarlatti G, von Gegerfelt A, Albert J, Biberfeld G, Chiodi F, Norrby E and **Fenyö EM**. Autologous neutralising antibodies prevail in HIV-2 but not in HIV-1 infection. *Virology* **193**, 528-530, 1993.
142. Zhang Y-j, Öhman P, Putkonen P, Albert J, Walther L, Stålhandske P, Biberfeld G and **Fenyö EM**. Autologous neutralizing antibodies to SIV_{sm} in cynomolgus monkeys correlate to prognosis. *Virology* **197**, 609-615, 1993.
143. Albert J, Björling E, von Gegerfelt A, Scarlatti G, Thorstensson R, Zhang Y-J and **Fenyö EM**. Antigen detection is a reliable method for evaluating HIV/SIV neutralization assays. *AIDS Res Human Retroviruses* **9**:501-504, 1993.
144. Sánchez-Palomino S, Rojas JM, Martínez MA, **Fenyö EM**, Nájera R, Domingo E and López-Galíndez C. Dilute passage promotes expression of genetic and phenotypic variants of human immunodeficiency virus type 1 in cell culture. *J Virol* **67**:2938-2943, 1993.
145. Report of a consensus workshop, Siena, Italy. Maternal factors involved in mother-to-child transmission of HIV-1. *J AIDS* **5**:1019-1029, 1992.

146. Scarlatti G, Hodara V, Rossi P, Muggiasca L, Bucceri A, Albert J and **Fenyö EM**. . Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype. *Virology* **197**:624-629 1993.
147. Karlsson A, Parsmyr K, Sandström E, **Fenyö EM**, and Albert J: MT-2 cell tropism as a prognostic marker for disease progression in HIV-1 infection. *J Clin. Microbiol.* **32**: 364-370, 1994.
148. Scarlatti G, Leitner T, Hodara V, Halapi E, Rossi P, Albert J and **Fenyö EM**. Neutralizing antibodies and viral characteristics in mother-to-child transmission of HIV-1. *AIDS, Suppl 2*, 1993.
149. **Fenyö EM**. Editorial comment. Viral phenotype and severity of HIV-1 infection: are children different from adults? *AIDS* **7**: 1673-4, 1993.
150. von Gegerfelt A, Diaz-Pohl C, **Fenyö EM** and Broliden K. Specificity of antibody-dependent cellular cytotoxicity in sera from human immunodeficiency virus type 2-infected individuals. *AIDS Res Hum Retrovir* **9**:883-889, 1993.
151. Fiore J, Björndal Å, Aperia-Peipke K, Di Stefano M, Pastore G, Gaines H, **Fenyö EM**, Albert J. The biological phenotype of HIV-1 is usually retained during and after sexual transmission. *Virology* **204**: 297-303, 1994.
152. **Fenyö EM**, Fiore J, Karlsson A, Albert J and Scarlatti G. Biological phenotypes of HIV-1 in pathogenesis and transmission. *Advanced Technol in Res, Diagn and Treatm of AIDS and in Oncol. Karger, Basel* **46**: 18-24, 1993.
153. Zhang Y-j, Putkonen P, Albert J, Öhman P, Biberfeld G, **Fenyö EM**. Stable biological and antigenic characteristics of HIV-2_{SBL6669} in nonpathogenic infection of macaques. *Virology* **200**: 583-589, 1994.
154. Valentin A, Albert J, Fredriksson R, **Fenyö EM** and Åsjö B. Dual tropism for lymphocytes and mononuclear phagocytes is a common feature of primary HIV-1 and HIV-2 isolates. *J Virol.* **68**: 6684-6689, 1994.
155. Karlsson A, Parsmyr K, Aperia K, Sandström E, **Fenyö EM**, Albert J. MT-2 tropism of HIV-1 isolates as a marker for response to treatment and development of drug resistance. *J Infectious Dis* **170**:1367 - 1375, 1994.
156. **Fenyö EM**. Antigenic variation of primate lentiviruses in humans and experimentally infected macaques. *Immunological Reviews* **140**: 131-146, 1994.
157. de Wolf F, Hogervorst E, Goudsmit J, **Fenyö EM**, Rübsamen-Waigmann H, Holmes H, Galvao-Castro B, Karita E, Wasi C, Sempala S.D.K, Baan E, Zorgdrager F, Lukashov V, Osmanov S, Kuiken C, Cornelissen M, and the WHO Network on HIV Isolation and Characterization. Syncytium inducing (SI) and non syncytium inducing (NSI) capacity of human immunodeficiency virus type 1 (HIV-1) subtypes other than B: Phenotypic and genotypic characteristics. *AIDS Res.Human Retroviruses* **10**: 1387-1400, 1994.
158. Rübsamen-Waigmann H, von Briesen H, Holmes H, Björndal Å, Korber B, Esser R, Ranjbar S, Tomlinson P, Galvao-Castro B, Karita E, Sempala S, Wasi C, Osmanov S, **Fenyö EM**, and other participants of the WHO Network for HIV Isolation and Characterization. Standard Conditions of Virus Isolation Reveal Biological Variability of HIV-1 in Different Regions of the World. *AIDS Res.Human Retroviruses* **10**: 1401-1408, 1994.

159. WHO Network for HIV Isolation and Characterization. HIV Type 1 variation in World Health Organization-sponsored vaccine evaluation sites: Genetic screening, sequence analysis and preliminary biological characterization of selected viral strains. *AIDS Res. Human Retroviruses* **10**: 1327-1344, 1994.
160. Yefenof E, Magyarlaki T, **Fenyö EM**, Wahren B and Klein E. Alternative complement pathway activation by CD4⁺ T cells of HIV infected individuals: A possible role in AIDS pathogenesis. *International Immunol* **6**: 1361-1366, 1994.
161. Luukkonen M, **Fenyö EM** and Schwartz S. Overexpression of human immunodeficiency virus type 1 protease increases intracellular cleavage of Gag and reduces virus infectivity. *Virology* **206**: 854-865, 1995.
162. **Fenyö EM**, Fiore J, Scarlatti G and Albert J. Viral markers of HIV-1 transmission. *Biotechnology and AIDS*, **36**:127-134, 1995.
163. Scarlatti G, Leitner T, Hodara V, Jansson M, Karlsson A, Wahlberg J, Rossi P, Uhlén M, **Fenyö EM** and Albert J. Interplay between HIV-1 phenotype and neutralizing antibody response in pathogenesis of AIDS. *in* *Retroviruses of Human AIDS and Related Animal Diseases*. Eds. M Girard and B Dodet. **9**: 103-107, 1994.
164. Grunow R, Franke L, Hinkula J, Wahren B, **Fenyö EM**, Jondal M and von Baehr R. Monoclonal antibodies to p24-core protein of HIV-1 mediate ADCC and inhibit virus spread in vitro. *Clinical and Diagnostic Virology* **3**: 221-231, 1995.
165. **Fenyö EM** and Rosen C. Overview Virology. *AIDS* **9** (suppl A): S1-S3, 1995.
166. Ratner L and **Fenyö EM**. Overview Virology. *AIDS* **10** (suppl A): S1-A2, 1996
167. **Fenyö EM**, Albert J and McKeating J. The role of the humoral immune response in HIV infection. *AIDS* **10** (suppl A): S97-S106, 1996.
168. **Fenyö EM**. HIV-1 biological phenotype varies with severity of infection across HIV-1 genetic subtypes. *in* *Development and Applications of Vaccines and Gene Therapy in AIDS*. Eds. Giraldo G, Bolognesi D P, Salvatore M, Beth-Giraldo E. **48**:49-55, 1996
169. Tan W, Schalling M, Zhao C, Luukkonen M, Nilsson M, **Fenyö EM**, Pavlakis G N, Schwartz S. Inhibitory activity of the equine infectious anemia virus major 5' splice site in the absence of rev. *J Virol* **70**:3645-3658, 1996.
170. **Fenyö EM** and Putkonen P. Broad cross-neutralizing activity in serum is associated with slow progression and low risk of transmission in primate lentivirus infections. *Immunology letters* **51**:95-99, 1996.
171. Kónya J, Stuber G, Björndal Å, **Fenyö EM**, Dillner J. Primary induction of human cytotoxic lymphocytes against a synthetic peptide of the HIV-1 protease. *J Gen Virol* **78**:2217-2224, 1997.
172. Palmer C, Balfe P, Fox D, May J C, Frederiksson R, **Fenyö EM**, McKeating J A. Functional characterisation of the V1V2 region of human immunodeficiency virus type I. *Virology* **220**:436-449, 1996.
173. McKeating J A, Zhang Y, Arnold C, Frederiksson R, **Fenyö EM**, Balfe P. Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera. *Virology* **220**: 450-460, 1996.
174. **Fenyö EM**, HIV biological phenotype: prognosis marker for transmission, disease progression and therapy. *J Biol. Regulators and Homeostatic Agents* **9**:88-90, 1996.

175. Weber J, **Fenyö EM**, Beddows S, Kaleebu P, Björndal Å, and the WHO Network for HIV Isolation and Characterisation. Neutralisation serotypes of HIV-1 field isolates are not predicted by genetic subtype. *J Virol* **70**:7827-7832, 1996.
176. Sabri F, Chiodi F, **Fenyö EM**. Lack of correlation between V3 amino acid sequence and syncytium capacity for some HIV type 1 isolates. *AIDS Res and Human Retroviruses* **12**:855-858, 1996.
177. Luukkonen M, Tan W, **Fenyö EM**, Schwartz S. Analysis of cross-reactivity of retrovirus protease using a vaccinia virus T7-RNA polymerase based expression system. *J Gen Virol* **76**:2169-2180, 1995.
178. Scarlatti G, Leitner T, Hodara V, Jansson M, Karlsson A, Wahlberg J, Uhlen M, **Fenyö EM**, Albert J. Interplay of HIV-1 phenotype and neutralizing antibody response in pathogenesis of AIDS. *Immunol Lett* **51**:23-28, 1996.
179. Zhang Y, Fadeel B, Hodara V and **Fenyö EM**. Induction of apoptosis by primary HIV-1 isolates correlates with productive infection in peripheral blood mononuclear cells. *AIDS* **11**:1219-1225, 1997.
180. Fiore J, Zhang Y, Björndal Å, Di Stefano M, Angarano G, Pastore G and **Fenyö EM**. Biological correlates of HIV-1 heterosexual transmission. *AIDS* **11**:1089-1094, 1997.
181. Mustafa F, Richmond J, Fernandez-Larsson R, Lu S, Fredriksson R, **Fenyö EM**, O'Connell M, Johnson E, Weng J, Santoro J and Robinson H. HIV-1 Env Glycoproteins from two series of primary isolates: Replication phenotype and immunogenicity. *Virology* **229**, 269-278, 1997.
182. **Fenyö EM** and Samuelsson A. HIV och Kemokinreceptorerna: Nya förklaringar till virusets biologi och virulens. *Läkartidningen* **94**, 824-828, 1997.
183. Expert Group of the Joint United Nations Programme on HIV/AIDS. Implications of HIV variability for transmission: scientific and policy issues. *AIDS* **11**:UNAIDS1-UNAIDS15, 1997.
184. Scarlatti G, Leitner T, Halapi E, Wahlberg J, Jansson M, Wigzell H, **Fenyö EM**, Albert J, Uhlén M and Rossi P. Analysis of the HIV-1 envelope V3-Loop sequences from ten mother - child pairs. *Annals of the New York Academy of Sciences*, **693**, 277-280, 1997.
185. Björndal Å, Deng H K, Jansson M, Fiore J R, Karlsson A, Albert J, Littman D R and **Fenyö EM**. Co-receptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. *J Virol* **71**:7478-7487, 1997.
186. Scarlatti G, Tresoldi E, Björndal Å, Fredriksson R, Colognesi C, Deng H K, Malnati M S, Plebani A, Siccardi A, Littman D R, **Fenyö EM**, Lusso P. Evolution of viral coreceptor usage and sensitivity to chemokines during the progression of the disease in children infected with human immunodeficiency virus type 1. *Nature Medicine* **3**:1259-1265, 1997.
187. Tscherning C, Alaeus A, Fredriksson R, Björndal Å, Deng H K, Littman D R, **Fenyö EM** and Albert J. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. *Virology* **241**:181-188, 1998.
188. Richmond J F L, Mustafa F, Lu S, Santoro J C, Weng J, O'Connell M O, **Fenyö EM**, Urwitz J L and Montefiori H L. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. *Virology* **230**:265-274, 1997.

189. Lawoko A.L, Johansson, B, Hjalmarsson S, Christensson B, Ljungberg , Al Khalili L, Sjölund W, Pipkorn R, Fenyö EM, Blomberg J: Comparative studies on neutralisation of primary HIV-I silodates by human sera and rabbit anti-V3 peptide sera. *J Med Virol* **59**: 169-179, 1999.
190. Lehner T, Biberfeld P, Boucher C, Darbyshire J, **Fenyö EM**, Heeney JL, Jager JC, Lundgren JD, Newell ML, Rösch P, Rossi P, Virelizier JL. European contribution to the science, prevention and management of HIV infection. *Vaccine* **15**:465-468, 1997.
191. Zhang Y-j, Fracasso C, Fiore JR, Björndal Å, Angarano G, Gringeri A, **Fenyö EM**. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. *J Inf Diseases* **176**:1180-1187, 1997.
192. Berger EA, Doms RW, **Fenyö EM**, Korber BTM, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J, and Weiss RA. A new classification for HIV-1. *Nature*, 1998. **391**:240.
193. Zhang Y-j, Fredriksson R, McKeating JA, and **Fenyö EM**. Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization. *Virology* **238**:254-264, 1997.
194. Corrigan GE, Al Khalili L, Malmsten A, Thorstensson R, **Fenyö EM**, Källander CFR, Gronowitz JS. RT activity determination highlights the failure of p24 assay to reliably quantify divergent HIV-1 in cell culture. *AIDS Res Hum Retroviruses* **14**:347-352, 1998.
195. Björndal Å, Sönnernborg A, Tscherning C, Albert J, **Fenyö EM**. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS-patients. *AIDS Res Hum Retroviruses*, 15:647-653, 1999.
196. Mörner A, Björndal Å, Albert J, KewalRamani V, Littman D, Inoue R, Thorstensson R, **Fenyö EM**, Björling E. Primary HIV-2 isolates, like HIV-1, frequently use CCR5 but show promiscuity in coreceptor usage. *J Virol*. **73**:2343-2349, 1999.
197. Tscherning C, Papadogiannakis N, Anvret M, Stolpe L, Lindgren S, Bohlin AB, Albert J, and **Fenyö EM**. The trophoblastic epithelial barrier is not infected in full-term placentae of human immunodeficiency virus-seropositive mothers undergoing antiretroviral therapy. *J Virol*. **73**:9673-9678, 1999.
198. **Fenyö EM**, Schuitemaker H, Åsjö B, McKeating J, Sattentau Q and the Concerted Action HIV Variability. The history of HIV-1 biological phenotypes: Past, present and future. *in: Human Retroviruses and AIDS* 1997. pp. III-13 - III-18.
199. Jansson M, Backström E, Björndal Å, Holmberg V, Rossi P, **Fenyö EM**, Popovic M, Albert J, and Wigzell H. Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS. *J Human Virol*. **2**:325-338, 1999.
200. Fiore JR, Buccoliero G, Pezzotti P, Rezza G, Saracino A, Pastore G, **Fenyö EM**, and Angarano G. HIV-1 disease progression in women: role of the viral phenotype of the HIV-positive steady partner. *AIDS* **13**:1801-1802, 1999.

201. Tscherning-Casper C, Vödrös D, Menu E, Aperia K, Fredriksson R, Dolcini G, Chaouat G, Barré-Sinoussi F, Albert J, **Fenyö EM**, and the European Network for In Utero Transmission of HIV-1. Coreceptor usage of HIV-1 isolates representing different genetic subtypes obtained from pregnant Cameroonian women. *J AIDS*, **24**:1-9, 2000.
202. Lawoko A, Johansson B, Ljunggren J, Fries A, Fredriksson R, Georgiewska L, Malmvall B, Pipkorn R, **Fenyö EM**, and Blomberg J. Structural prerequisites for inter-subtype B and D antigenicity of the third variable envelope region (V3) of HIV-1. *J Infect Dis* **182**:49-58, 2000.
203. Bastiani Lallo L, Cecilia D, **Fenyö EM**, Laal S, and Zolla-Pazner S. HIV-1 phenotype correlates with the relative amounts of LFA-1 and MHC class II in the virion envelope. *AIDS* **14**:1523-31, 2000.
204. **Fenyö EM**. Biological phenotype and coreceptor usage of human immunodeficiency virus. *Acta Microbiol. Immunol. Hungarica*. **47**:131-142, 2000.
205. Vödrös D, Thorstensson R, Biberfeld G, Schols D, De Clercq E, and **Fenyö EM**. Coreceptor usage of sequential isolates from cynomolgus monkeys experimentally infected with Simian immunodeficiency virus (SIVsm). *Virology* **291**:12-21, 2001.
206. Tscherning-Casper C, Dolcini G, Maucière P, **Fenyö EM**, Barré-Sinoussi F, Albert J, Menu E and the European Network on the Study of *In Utero* Transmission of HIV-1. Evidence of the existence of a new circulating recombinant form of HIV type 1 subtype A/J in Cameroon. *AIDS Res Hum Retroviruses* **16**:1313-1318, 2000.
207. Menu E, Mognetti B, Moussa M, Nardese V, Tresoldi E, Tscherning C, Mbopi Keou FX, Dubachet S, Mauciere P, **Fenyö EM**, Scarlatti G, Barre-Sinoussi F, Chaouat G, and the BIOMED2 Working Group on the in utero transmission of HIV-1. Early pregnancy: *Biology and Medicine* **3**:245-258, 1997.
208. Vödrös D, Tscherning-Casper C, Navea L, Schols D, De Clercq E, and **Fenyö EM**. Quantitative evaluation of HIV-1 coreceptor use in the GHOST(3) cell assay. *Virology* **291**:1-11, 2001.
209. Casper C, Naver L, Clevestig P, Belfrage E, Leitner T, Albert J, Lindgren S, Ottenblad C, Bohlin AB, **Fenyö EM**, Ehrnst A. Coreceptor change appears after immune deficiency is established in children infected with different HIV-1 subtypes. *AIDS Res Hum Retroviruses* **18**:343-52, 2002.
210. Casper C.H.E, Clevestig P, Carlenor E, Leitner T, Anzén B, Lidman K, Belfrage E, Albert J, Bohlin AB, Ottenblad C, Navér L, Lindgren S, **Fenyö EM**, and Ehrnst A. Link between the X4 phenotype in human immunodeficiency virus type 1-infected mothers and their children, despite the early presence of R5 in the child. *J Inf Dis* **186**:914-921, 2002.
211. Losman B, Bolmstedt A, Schönning K, Björndal Å, Westin C, **Fenyö EM**, and Olofsson S. Protection of neutralization epitopes in the V3-loop of oligomeric human

- immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region. *AIDS Res Hum Retroviruses* **17**:1067-1076, 2001.
212. Casper C, and **Fenyö EM**. Mother-to-child transmission of HIV-1: The role of HIV-1 variability and the placental barrier. *Acta Microbiol. Immunol. Hungarica* **48**:545-573, 2001.
213. **Fenyö EM**. The role of virus biological phenotype in human immunodeficiency virus pathogenesis. *AIDS Reviews* **3**:157-168, 2001.
214. Report from a meeting of the WHO-UNAIDS Vaccine Advisory Committee, Geneva, 21-23 February 2000. Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1. *AIDS* **15**:W1-W25, 2001.
215. Shi Y, Albert J, Francis G, Holmes H, and **Fenyö EM**. A new cell line-based neutralisation assay for primary HIV-1 isolates. *AIDS Res Hum Retroviruses* **18**:957-967, 2002.
216. **Fenyö EM**, Mullins J, Korber B, Beddows S, and Weber J. WHO-UNAIDS Guidelines for Standard HIV Isolation and Characterisation Procedures. Second Edition, 2002.
217. Vödrös D, Thorstensson R, Doms RW, **Fenyö EM** and Reeves JD. Evolution of coreceptor use and CD4-independence in envelope clones derived from SIVsm-infected macaques. *Virology* **316**:17-28, 2003.
218. Report from a WHO-UNAIDS Consultation 13-15 March 2001, Geneva, Switzerland. Scientific considerations for the regulation and clinical evaluation of HIV/AIDS preventive vaccines. *AIDS* **16**:W15-W25, 2002.
219. Karlsson I, Antonsson L, Shi Y, Karlsson A, Albert J, Leitner T, Olde B, Owman C and **Fenyö EM**. HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. *AIDS* **17**:2561-2569, 2003.
220. Karlsson I, Antonsson L, Shi Y, Öberg M, Karlsson A, Albert J, Olde B, Owman C, Jansson M and **Fenyö EM**. Coevolution of RANTES sensitivity and mode of CCR5 receptor use by HIV-1 of R5 phenotype. *J Virol* **78**:11807-11815, 2004.
221. Vödrös D and **Fenyö EM**. Primate models for human immunodeficiency virus infection. *Acta Microbiol. Immunol. Hungarica* **51**:1-29, 2004.
222. Clevestig P, Malikovic I, Casper C, Carlenor E, Lindgren S, Navér L, Bohlin A-B, **Fenyö EM**, Leitner T, and Ehrnst A. The X4 phenotype of HIV type 1 evolves from R5 in two children of mothers, carrying X4, and is not linked to transmission. *AIDS Res Hum Retroviruses* **21**:371-378, 2005.
223. Vödrös D and **Fenyö EM**. Quantitative evaluation of HIV and SIV co-receptor use with GHOST(3) cell assay. *Human Retrovirus Protocols*. Ed: Tuofu Zhu. Humana Press Chapter 26:333-342, 2005.

224. Nordqvist A and **Fenyö EM**. Plaque reduction assays for human and simian immunodeficiency virus neutralisation. *Human Retrovirus Protocols*. Ed: Tuofu Zhu. Humana Press Chapter 26:273-285, 2005.
225. Karlsson I, Grivel J-C, Chen SS, Karlsson A, Albert J, Fenyö EM and Margolis M. Differential pathogenesis of primary CCR5-using human immunodeficiency virus type 1 isolates in ex vivo human lymphoid tissue. *J Virol* **79**:11151-11160, 2005.
226. Repits J, Öberg M, Esbjörnsson J, Medstrand P, Karlsson A, Albert J, Fenyö EM and Jansson M. Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. *J Gen Virol* **86**:2859-2869, 2005.
227. Lauren A, Thorstensson R, Fenyö EM. Comparative studies on mucosal and intravenous transmission of simian immunodeficiency virus (SIVsm): the kinetics of evolution to neutralization resistance are related to progression rate of disease. *J Gen Virol*. **87**:595-606, 2006.
228. Lauren A, Vodros D, Thorstensson R, Fenyö EM. Comparative studies on mucosal and intravenous transmission of simian immunodeficiency virus (SIVsm): evolution of coreceptor use varies with pathogenic outcome. *J Gen Virol*. **87**:581-94, 2006.
229. Casper C, Mild M, Jansson M, Karlsson A, Holmberg V, Bratt G, Van Paaschen H, Biberfeld P, Bjorndal A, Albert J, Popovic M, **Fenyö EM**. Coreceptor usage of primary HIV type 1 isolates obtained from different lymph node subsets. *AIDS Res Hum Retroviruses*. **21**:1003-10, 2005.
230. Shi Y, Brandin E, Vincic E, Jansson M, Blaxhult A, Gyllensten K, Moberg L, Brostrom C, **Fenyö EM**, Albert J. Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. *J Gen Virol*. **86**:3385-96, 2005.
231. Mild M, Bjorndal A, Medstrand P, **Fenyö EM**. Isolation of human immunodeficiency virus-type 1 (HIV-1) clones with biological and molecular properties of the primary isolate. *Virology*. **350**:58-66, 2006.
232. Martensson UE, **Fenyö EM**, Olde B, Owman C. Characterization of the human chemerin receptor--ChemR23/CMKLR1--as co-receptor for human and simian immunodeficiency virus infection, and identification of virus-binding receptor domains. *Virology*. **355**:6-17, 2006.
233. Mild M, Esbjörnsson J, **Fenyö EM**, Medstrand P. Frequent inpatient recombination between human immunodeficiency virus type 1 R5 and X4 envelopes: implications for coreceptor switch. *J Virol*. **81**:3369-76, 2007.
234. Lauren A, Vincic E, Hoshino H, Thorstensson R, **Fenyö EM**. CD4-independent use of the CCR5 receptor by sequential primary SIVsm isolates. *Retrovirology*. **4**:50, 2007.
235. Ripamonti C, Leitner T, Laurén A, Karlsson I, Pastore A, Cavarelli M, Antonsson L, Plebani A, **Fenyö EM** and Scarlatti G. Biological and genetic evolution of HIV-1 in

- two siblings with different patterns of disease progression. *AIDS Res Hum Retroviruses*. **23**:1531-40, 2007.
236. Sterjovski J, Churchill MJ, Ellett A, Gray LR, Roche MJ, Dunfee RL, Purcell DFJ, Saksena N, Wang B, Sonza S, Wesselingh SL, Karlsson I, **Fenyö EM**, Gabuzda D, Cunningham AL and Gorry PR. Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. *Retrovirology* 2007, **4**:89.
237. Månsson F, Alves A, Silva ZJ, Dias F, Andersson S, Biberfeld G, **Fenyö EM**, Norrgren H. Trends of HIV-1 and HIV-2 prevalence among pregnant women in Guinea-Bissau, West Africa: possible effect of the civil war 1998 1999. *Sex Transm Infect*. **83**:463-7, 2007.
238. Albert J, Chiodi F, **Fenyö EM**. Introduction: HIV neutralizing antibodies: relevance to pathogenesis and vaccines. *J Intern Med*. 2007 **262**:2-4, 2007. Review.
239. Nowroozalizadeh S, Jansson M, Adamsson J, Lindblad M, **Fenyö EM**, Holmgren J and Harandi A. Suppression of HIV replication *in vitro* by CpG and CpG conjugated to the non toxic B subunit of cholera toxin. *Current HIV Research*, **6**:230-8, 2008.
240. Ellmark P, Andersson H, Abayneh S, **Fenyö EM**, and Borrebaeck CAK. Identification of a strongly activating human anti-CD-40 antibody that suppresses HIV-1 infection. *AIDS Res Hum Retroviruses*. **24**:367-73, 2008.
241. Abayneh S, Ellmark P, Karlsson U, Karlsson I and **Fenyö EM**. Sensitivity of HIV-1 primary isolates to human anti-CD40 antibody-mediated suppression is related to co-receptor use. *AIDS Res Hum Retroviruses*. **24**:447-52, 2008.
242. Laurén A and **Fenyö EM**. Implications from the SIV model in understanding HIV neutralization. *Future HIV Therapy*, **2**:47-58, 2008. Review.
243. Polonis VR, Brown BK, Borges AR, Zolla-Pazner S, Dimitrov DS, Zhang MY, Barnett SW, Ruprecht RM, Scarlatti G, **Fenyö EM**, Montefiori DC, McCutchan FE, Michael NL. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. *Virology* **375**:315-20, 2008. Review
244. Repits J, Sterjovski J, Badia-Martinez D, Mild M, Gray L, ChurchillMJ, Purcell DFJ, Karlsson A, Albert J, **Fenyö EM**, Achour A, Gorry P and Jansson M. Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. *Virology* **379**:125-134, 2008.
245. Cavarelli M, Karlsson I, Zanchetta M, Antonsson L, Plebani A, Giaquinto C, **Fenyö EM**, De Rossi A and Scarlatti G. HIV-1 with multiple CCR5/CXCR4 chimeric receptor use is predictive of immunological failure in infected children. *PLoS ONE* **3** e3292. Epub 2008.
246. **Fenyö EM**, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, Donners H, Heyndrickx L, Alcamí J, Bongertz V, Jassoy C, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Sattentau Q, Schuitemaker H, Sutthent R, Wrin T,

- Scarlati G. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS ONE. 2009;4(2):e4505. Epub 2009.
247. Nowroozalizadeh S, Månsson F, Silva ZD, Repits J, Dabo B, Pereira C, Biague A, Albert J, Nielsen J, Aaby P, **Fenyö EM**, Norrgren H, Holmgren B, Jansson M. Studies on toll-like receptor stimuli responsiveness in HIV-1 and HIV-2 infections. Cytokine. 46(3):325-31. Epub 2009
248. Mild M, Kvist A, Esbjörnsson J, Karlsson I, **Fenyö EM** and Medstrand P. Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection Infection, Genetics and Evolution, 2009 May 14.
249. Wade J, Sterjovski J, Gray L, Roche M, Chiavaroli L, Ellett A, Jakobsen MR, Cowley D, Pereira Cda F, Saksena N, Wang B, Purcell DF, Karlsson I, **Fenyö EM**, Churchill M, Gorry PR. Enhanced CD4+ cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection. Virology. 396(2):246-55. Epub 2009
250. Hinkula J, Walther-Jallow L, Laurén A, Mäkitalo B, Oberg M, Wahren B, **Fenyö EM**, Spetz AL. Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells. Vaccine, 27(46):6424-31. Epub 2009
251. Månsson F, Biague A, da Silva ZJ, Dias F, Nilsson LA, Andersson S, **Fenyö EM**, Norrgren H. Prevalence and incidence of HIV-1 and HIV-2 before, during and after a civil war in an occupational cohort in Guinea-Bissau, West Africa. AIDS 23(12):1575-82, 2009
252. Esbjörnsson J, Månsson F, Martinez-Arias W, Vincic E, Biague A, da Silva ZJ, **Fenyö EM**, Norrgren H, Medstrand P. Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease – indication of an evolving epidemic in West Africa. Retrovirology 7:23, 2010
253. Biague A, Månsson F, da Silva Z, Dias F, Nantote Q, Costa J, Andersson S, Naucler A, Biberfeld G, **Fenyö EM**, Norrgren H. [High sexual risk taking and diverging trends of HIV-1 and HIV-2 in the military of Guinea Bissau.](#) J Infect Dev Ctries. 2010 Jun 3;4(5):301-8.
254. Nowroozalizadeh S, Månsson F, da Silva Z, Repits J, Dabo B, Pereira C, Biague A, Albert J, Nielsen J, Aaby P, **Fenyö EM**, Norrgren H, Holmgren B, Jansson M. [Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections.](#) J Infect Dis. 2010 Apr 15;201(8):1150-4.
255. Tranell A, Fenyö EM, Schwartz S. [Serine- and arginine-rich protein 55 and 75 \(SRp55 and SRp75\) induce production of HIV-1 vpr mRNA by inhibiting the 5'-splice site of exon 3.](#) J Biol Chem. 2010 Oct 8;285(41):31537-47. Epub 2010 Aug 4.
256. Cavarelli M, Karlsson I, Ripamonti C, Plebani A, Fenyö EM, Scarlati G. [Flexible use of CCR5 in the absence of CXCR4 use explains the immune deficiency in HIV-1 infected children.](#) AIDS. 2010 Oct 23;24(16):2527-33.

257. Ozkaya Sahin G, Bowles EJ, Parker J, Uchtenhagen H, Sheik-Khalil E, Taylor S, Pybus OG, Mäkitalo B, Walther-Jallow L, Spångberg M, Thorstensson R, Achour A, Fenyö EM, Stewart-Jones GB, Spetz AL. [Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy.](#) PLoS Pathog. 2010 Sep 2;6(9):e1001084.
258. Månsson F, Camara C, Biague A, Monteiro M, da Silva Z J, Dias F, Alves A, Andersson S, Fenyö E M, Norrgren H and Unemo M. High prevalence of HIV-1, HIV-2 and other sexually transmitted infections among women attending two sexual health clinics in Bissau, Guinea-Bissau, West Africa. International Journal of STD & AIDS 2010; 21: 631–635.
259. Vinner L, Holmgren B, Jensen JK, Esbjörnsson J, Borggren M, Hentze JL, Karlsson I, Andresen BS, Gram GJ, Kloverpris H, Aaby P, da Silva ZJ, Fenyö EM and Fomsgaard A. [Sequence analysis of HIV-1 isolates from Guinea-Bissau: selection of vaccine epitopes relevant in both West African and European countries.](#) APMIS. 2011 Aug;119(8):487-97. Epub 2011 May 14.
260. Fenyö EM, Esbjörnsson J, Medstrand P, Jansson M. [Human immunodeficiency virus type 1 biological variation and coreceptor use: from concept to clinical significance.](#) J Intern Med. 2011 Dec;270(6):520-31. doi: 10.1111/j.1365-2796.2011.02455.x. Epub 2011 Oct 27.
261. Ozkaya Sahin G, Holmgren B, da Silva Z, Nielsen J, Nowroozalizadeh S, Esbjörnsson J, Månsson F, Andersson S, Norrgren H, Aaby P, Jansson M, Fenyö EM. [Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 \(HIV-2\) from HIV-1.](#) J Virol. 2012 Jan;86(2):961-71. Epub 2011 Nov 9.
262. Heyndrickx L, Heath A, Sheik-Khalil E, Alcamí J, Bongertz V, Jansson M, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Ramaswamy M, Sattentau Q, Tolazzi M, Schuitemaker H, Willems B, Wrin T, Fenyö EM, Scarlatti G. [International network for comparison of HIV neutralization assays: the NeutNet report II.](#) PLoS One. 2012;7(5):e36438. Epub 2012 May 9.
263. Esbjörnsson J, Månsson F, Kvist A, Isberg PE, Nowroozalizadeh S, Biague AJ, da Silva ZJ, Jansson M, Fenyö EM, Norrgren H, Medstrand P. [Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection.](#) N Engl J Med. 2012 Jul 19;367(3):224-32.
264. Özkaya Şahin G, Holmgren B, Sheik-Khalil E, da Silva Z, Nielsen J, Nowroozalizadeh S, Månsson F, Norrgren H, Aaby P, Fenyö EM, Jansson M. [Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent.](#) J Virol. 2013 Jan;87(1):273-81. Epub 2012 Oct 17. PMID:23077299
265. Özkaya Şahin G, Månsson F, Palm AA, Vincic E, da Silva Z, Medstrand P, Norrgren H, Fenyö EM, Jansson M. [Frequent intratype neutralization by plasma immunoglobulin a identified in HIV type 2 infection.](#) AIDS Res Hum Retroviruses. 2013 Mar;29(3):470-8. Epub 2012 Nov 21. PMID:23088167

266. Mild M, Gray RR, Kvist A, Lemey P, Goodenow MM, Fenyö EM, Albert J, Salemi M, Esbjörnsson J, Medstrand P. [High inpatient HIV-1 evolutionary rate is associated with CCR5-to-CXCR4 coreceptor switch](#). *Infect Genet Evol*. 2013 Oct;19:369-77. Epub 2013 May 11. PMID:23672855
267. Esbjörnsson J, Månsson F, Kvist A, Isberg PE, Nowroozalizadeh S, Biague AJ, da Silva ZJ, Jansson M, Fenyö EM, Norrgren H, Medstrand P. [Effect of HIV-2 infection on HIV-1 disease progression and mortality](#). *AIDS*. 2014 Feb 20;28(4):614-5. No abstract available. PMID:24469002
268. Esbjörnsson J, Månsson F, Kvist A, Isberg PE, Biague AJ, da Silva ZJ, Jansson M, Fenyö EM, Norrgren H, Medstrand P. [Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals](#). *AIDS*. 2014 Apr 24;28(7):949-57. PMID:24812673
269. Sheik-Khalil E, Bray MA, Ozkaya Ahin G, Scarlatti G, Jansson M, Carpenter AE, Fenyö EM. [Automated image-based assay for evaluation of HIV neutralization and cell-to-cell fusion inhibition](#). *BMC Infect Dis*. 2014 Aug 30;14(1):472. [Epub ahead of print] PMID:25176034